In a strategic move to improve cancer care, Johnson & Johnson MedTech has partnered with Qure.ai to enable early detection of lung cancer across India. The collaboration focuses on identifying the disease at its most treatable stage, significantly improving patient outcomes.
Project BreatheEZ: AI-Powered Screening Clinics Across India
As reported by thehindubusinessline, this partnership is part of Project BreatheEZ, a joint initiative aimed at setting up AI-led Incidental Pulmonary Nodule (IPN) Detection Clinics in top hospitals across the country. These clinics will leverage Qure.ai’s artificial intelligence technology to detect early signs of lung cancer through advanced image screening.
Addressing a Critical Healthcare Gap
Anuj Virmani, Managing Director – India, Johnson & Johnson MedTech, emphasized the urgency of the project.
“Lung cancer remains one of the leading causes of cancer-related deaths among both men and women. In India, patients—especially in tier-2 and tier-3 cities—face considerable barriers to timely diagnosis, which delays access to life-saving treatment.”
AI to Flag Suspicious Nodules in Imaging
Through this collaboration, the clinics will screen and flag suspicious nodules detected in X-rays and CT scans—nodules that may potentially be cancerous. By doing so, doctors can take early action, increasing the chances of successful treatment.
A Step Toward Equitable Cancer Care
Ultimately, this initiative aims to bridge the diagnostic gap in underserved areas by combining cutting-edge AI tools with clinical expertise. With earlier detection and faster diagnosis, Project BreatheEZ aims to improve outcomes. It is poised to reduce lung cancer mortality in India.